In new remarks to the US government, several medical organizations say that mergers of major corporations, such as CVS Health and Aetna, have had critical anti-competitive results without increasing the price and characteristics of health care.
The Alliance for Pharmacy Compounding, American Pharmacists Association, American Society of Consultant Pharmacists, National Alliance of State Pharmacy Associations, and National Community Pharmacists Association are urging together antitrust policy change in a joint commentary to the Federal Trade Commission and the Department of Justice Antitrust Division.
Earlier this year, the companies have offered new guidelines for learning how to evaluate and whether to support potential mergers seeking to combine firms that don’t compete with one another but operate in the same supply chain.
In the previous interviews of the CVC government, they mentioned the following: As a combined company, we are working to transform the consumer health experience and build healthier communities by offering care that is local, easier to use, less expensive, and puts consumers at the center of their attention.
The Regulatory Government
Citing the CVS Health/Aetna and Cigna/Express Scripts mergers as well as the OptumRx affiliation with UnitedHealthcare, the pharmacy organizations stated that vertical merger in the pharmacy sector had yielded anti-competitive results without guaranteed increases in cost or level of care.
The companies should create a regulatory government that does not allow these actions to harm health care access, quality unduly, and service, the organizations supported.
In the science sector, the three largest pharmacy benefit administrators (PBMs) control more than three-quarters of all prescriptions filled in America–equaling over 3.3 billion prescriptions, the groups wrote.
“Each of these PBMs has been linked with other, equally powerful organizations in the healthcare value chain. This surge in upward consolidation has created an oligopoly of combined healthcare companies controlling nearly all aspects of the healthcare and pharmacy supply chain,” the groups addressed.
The Consumer Report
Despite claims of enhanced efficiencies, the CVS Health/Aetna merger has not produced lower costs for consumers, according to the groups. Consumer Reports found that CVS drugstores often have the highest retail prices —400% higher than objective pharmacies‘ retail prices for the same prescription medications, according to the organizations.
“As patients’ out-of-pocket costs and premiums continue to rise, while quality and service levels decline, the companies need to be as skeptical of effectiveness claims in vertical activities as they are in horizontal transactions.”
A growing body of analysis evidence, including from current and former agency officials, notes that vertical consolidation in health care has led to increased prices without compensating improvements in quality, they wrote.
“Given the evidence of anti-competitive harm from vertical concentration, we ask the federal antitrust enforcement agencies to consider renewed approaches to tackling concentration in the health care sector.” the cost and quality of health care.
Wrapping Up
Healthcare sphere is currently on the top of the popularity, yet there are lots of companies which are not ready to compete with their rivals in quality case, so they do it utilizing increasing the drug price. Those organizations usually fail. Hope, in the nearest future, there will not be new dramatic price increases in the pharmacological area.
Be the first to comment on "Pharmacy Groups Endure Difficulties With Health Care Megamergers"